PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
PTC Therapeutics delivered a strong Q2 with total revenue of $361 million and product revenue jumping over 100% year-over-year to $239 million, driving a swing to net income of $83.5 million. Management raised full-year 2026 total revenue guidance to $1.18 billion to $1.28 billion and increased product revenue expectations to $850 million to $950 million, citing continued momentum for Sephience.
Key figures
- Eps
- 0.92
- Revenue
- 361000000
- Guidance
- Full-year 2026 total revenue $1.18B-$1.28B; product revenue raised to $850M-$950M from $750M-$850M
- Revenue Yoy
- over 100%
- Net income
- 83500000
- Product revenue
- 239000000
- Sephience revenue
- 151000000
- Novartis milestone
- 50000000
- Debt offering proceeds
- 550000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.